October 17, 2023 07:03 AM EDTUpdated 09:30 AM
Manufacturing

Lon­za braces for 2024 prof­it im­pact due to Mod­er­na, Ko­di­ak man­u­fac­tur­ing cuts

Anna Brown

News Reporter

Lon­za is prepar­ing for prof­it im­pact in 2024 be­cause of over­all biotech fund­ing con­straints, topped off by Mod­er­na’s con­tract can­cel­la­tion and its ex­pect­ed small­er busi­ness …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times